Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 5/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP12 | P39900 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbamic Acid SCHEMBL4407325 | 0.96 | NLRP3 (0.44) | NLRP3POLBKDM4ECACNA1BMMP1 | |
| Carbamic Acid SCHEMBL4407322 | 0.96 | NLRP3 (0.44) | NLRP3POLBKDM4ECACNA1BMMP1 | |
| SCHEMBL4404884 | 0.81 | TRPM2 (0.49) | POLBKDM4EMMP1MMP2MMP9 | |
| SCHEMBL4404890 | 0.81 | TRPM2 (0.49) | POLBKDM4EMMP1MMP2MMP9 | |
| SCHEMBL1095326 | 0.80 | NLRP3 (0.61) | NLRP3POLBKDM4ELMNAMAPT | |
| SCHEMBL9147553 | 0.79 | SMN1; SMN2 (0.50) | KDM4ECACNA1BMMP1MMP2MMP9 | |
| SCHEMBL9147560 | 0.79 | SMN1; SMN2 (0.50) | KDM4ECACNA1BMMP1MMP2MMP9 | |
| SCHEMBL6929631 | 0.78 | NPC1 (0.63) | NLRP3POLBKDM4ELMNACASP3 | |
| SCHEMBL4955339 | 0.75 | L3MBTL1 (0.57) | POLBKDM4EMAPT | |
| SCHEMBL11229669 | 0.74 | MMP1 (0.52) | KDM4ECACNA1BMMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7429658-B2 | Synthesis of protected pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2008-09-30 | — | — | US | disclosed |
| US-20060264622-A1 | Synthesis of protected pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264622-A1 | Synthesis of protected pyrrolobenzodiazepines | SBDS, DRD2, GRIN2D | NLRP3 2610/4885POLB 383/4885KDM4E 1423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.